Table 1. Patient characteristics (n=170).
| Characteristics | Median [range] | No. (%) |
|---|---|---|
| Age, y | 57 [21-91] | |
| Months from diagnosis | 70 [4-268] | |
| Months on imatinib | 40 [1-108] | |
| Imatinib failure | ||
| Resistance | 137 (81) | |
| Intolerance | 33 (19) | |
| Prior interferon therapy | 91 (54%) | |
| Best response to imatinib | ||
| CCyR | 44 (26) | |
| PCyR | 34 (20) | |
| mCyR | 23 (14) | |
| CHR | 53 (31) | |
| No response | 16 (9) | |
| Mutations at start of latest TKI | 57/128 (45) | |
| Mutations among resistant patients | 55/137 (40) | |
| % Ph at start of TKI | 100 [0-100]* | |
| 2nd line TKI | ||
| Nilotinib | 28 (16) | |
| Dasatinib | 67 (39) | |
| Bosutinib | 41 (24) | |
| INNO-406 | 4 (2) | |
| 3rd line TKI | ||
| Nilotinib | 3 (2) | |
| Dasatinib | 6 (4) | |
| Bosutinib | 12 (7) | |
| INNO-406 | 5 (3) | |
| 4th line TKI | ||
| Nilotinib | 3 (2) | |
| INNO-406 | 1 (1) |
*
4 patients with intolerance to imatinib started 2nd TKI with a CCyR. All 4 of these patients maintained a CCyR.